Anton Pekcec

Company: Boehringer Ingelheim

Job title: Director, Cardiometabolic Diseases Research

Seminars:

Innovating GLP-1 Mono-Agonist Development for Refined Efficacy & Safety to Expand Patient Accessibility 10:30 am

Enhancing peptide stability and half-life for reduced dosing frequency to improve patient convenience for greater adherence Minimizing gastrointestinal side effects for improved patient comfort to increase treatment acceptance for wider clinical adoption Exploring novel delivery technologies for alternative administration routes to broaden patient access for diverse therapeutic needsRead more

day: Day One